Annals of Internal Medicine, 149 (9), 601611
PHASE 2 OBESITY TRIAL Triple-Hormone Receptor Agonist Retatrutide for Obesity A Phase 2 Trial Published in the New England Journal of Medicine in 2023, this study reported substantial reductions in body weight across multiple dose groups and helped establish Retatrutide as one of the most closely followed compounds in obesity research
Long trials and reviews have not confirmed that link, and the early fears have largely been dispelled (Jalleh 2026)
In the same cell line stressed with rotenone, GLP-1 receptor agonists, GIP receptor agonists, and the dual GLP-1/GIP receptor agonist, D-Ala2-GIP-glu-PAL, improved Akt activation [141]
You may also find a decreased desire to consume alcohol and smokers may even want to quit smoking
Instead of taking them at once, prioritize a separation of a few hours between the two